Investigator Perspectives

Investigator Perspectives

Targeted Oncology presents Investigator Perspectives, a video series featuring key opinion leaders discussing how to approach and manage patients with different tumor types.

Novel Immune Checkpoint Inhibitors in Advanced Cervix Cancer

December 17th 2021

David M. O’Malley, MD, explores the use of PD-L1 inhibitors and CTLA-4 inhibitors for the treatment of recurrent/metastatic cervical cancer.

Advanced/Metastatic Cholangiocarcinoma Treatment Landscape

December 3rd 2021

Expert perspective from Anthony B. El-Khoueiry, MD, who reviews the evolving treatment landscape of targeted therapy for advanced/metastatic cholangiocarcinoma.

The CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

December 1st 2021

Recommendations for treating advanced renal cell carcinoma with the combination of lenvatinib plus pembrolizumab or lenvatinib plus everolimus, as suggested by Memorial Sloan Kettering Cancer Center’s Chung-Han Lee, MD, PhD, and Kiran Kehoe, RN, BSN, CCRN.

Transarterial Yttrium-90 Radioembolization with Chemotherapy for the Treatment of Colorectal Liver Metastasis: The EPOCH Study

November 1st 2021

Mary F. Mulcahy, MD, breaks down the phase III EPOCH study and explains how it has affected the treatment of colorectal cancer with liver metastasis.

Prostate Cancer: The VISION Trial

October 19th 2021

Scott T. Tagawa, MD, FACP, reviews the use of 177Lu-PSMA-617 radioligand therapy and clinical implications from the phases 3 VISION trial for patients with metastatic castration-resistant prostate cancer (mCRPC).

Metastatic Castrate-Resistant Prostate Cancer Treatment: Updates on Use of Darolutamide

October 18th 2021

Karim Fizazi, MD, PhD, provides a discussion on metastatic castrate-resistant prostate cancer and the use of darolutamide for management.

Transplant Ineligible Multiple Myeloma: Updates to the MAIA Study

September 30th 2021

Considerations for updated data from the MAIA study of daratumumab plus lenalidomide and dexamethasone, and how they fit into the optimal management of transplant-ineligible newly diagnosed multiple myeloma.

Acute Myeloid Leukemia: Advances in Initial Therapy

September 24th 2021

Daniel Pollyea, MD, MS, discusses the current treatment options for acute myeloid leukemia.

Advances in the Treatment of Myelodysplastic Syndrome: Targeting CD47

September 22nd 2021

Naval Daver, MD, explains the current and emerging treatment options for myelodysplastic syndrome.

Metastatic Colorectal Cancer: Advances in Non-Chemotherapy Treatment Options

September 13th 2021

John Marshall, MD, discusses the realities of metastatic colorectal cancer management and therapy options to consider outside of chemotherapy—regorafenib, in particular.